Novavax Reports Fourth Quarter and Full Year 2021 Financial

/PRNewswire/ -- NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union,...

Related Keywords

Australia , Japan , Vietnam , Republic Of , Philippines , United States , United Kingdom , South Africa , United Arab Emirates , Indonesia , Canada , Mexico , Bangladesh , India , Thailand , New Zealand , Israel , Singapore , South Korea , Switzerland , Great Britain , Laura Keenan Lindsey , Erika Schultz , Stanleyc Erck , Alexandra Roy , Alison Chartan , Combination Vaccine Clinical Development , Instagram , Linkedin , Twitter , Vaccine Clinical Development , Israel Ministry Of Health , Takeda Pharmaceutical Company , Coalition For Epidemic Preparedness Innovations , Nasdaq , European Union , Facebook , Serum Institute Of India , Novavax Inc , University Of Southampton , World Health Organization , European Commission , Exchange Commission , United Kingdom Phase , Chief Executive Officer , Multiple Regulatory Authorizations Globally , Biologics License Application , Serum Institute , Multiple Regulatory Submissions Globally , Pharmaceutical Company Limited , New Drug , Advanced Purchase , Boost Phase , Influenza Combination Vaccine Clinical , New England Journal , Lancet Respiratory , Twelve Months Ended December , Epidemic Preparedness , World Health , Financial Condition , Novavax Annual Report , Quarterly Reports , Keenan Lindsey , Novavax , Nc ,